- Posted By: TreehillPartners
- In: Did you know?, Drug Development
Whilst Corona virus news are out there loud and clear, a mindset of “I would survive hence will be taking my chance” made us pause and reply, calmly, that yes you likely would but could carry it to those who would not – and that is the problem. We point out the often quoted comparison of 1918 flu epidemic responses between the two cities...
- Posted By: TreehillPartners
- In: Drug Development, Strategy & Corporate Development
Rising awareness and emergence of differentiated solutions for multiple psychiatric and mental health conditions is an ongoing theme of innovation in pharma but also adjacent and “convergence” fields in healthcare. Increasing incidence, certainly exacerbated by lockdowns and other measures implemented to curtail the spread of COVID-19, and the significant lack of innovation in the past represent the key ingredients for a resurgence, which is currently emerging.
- Posted By: TreehillPartners
- In: Drug Development, Strategy & Corporate Development
Capital allocation towards innovative health-tech solutions has fuelled an increase in adoption of digital technologies. We outline a few current themes and future trends in the area.
- Posted By: TreehillPartners
- In: Dealmaking, Financing & Capital Markets
A month into 2022 and all virtual “JPM meetings” completed, we took a moment to reflect on the past
- Posted By: TreehillPartners
- In: Leadership & Restructuring, Strategy & Corporate Development
The UK Government and EU Commission trumpeted their last minute Brexit trade deal, struck at the end of December, as comprehensive, the biggest yet. Even allowing for the hyperbole of politicians, a closer inspection of the EU-UK Trade and Cooperation Agreement (TCA) renders these statements illusory for the pharma sector. In this article we summarise the extent to which the TCA really assists businesses in the sector to overcome the separation of the UK and the EU into two separate markets:
- Posted By: TreehillPartners
- In: Business Development & Licensing, Dealmaking
The start of a new year in healthcare has over the past decades been characterized by back-to-back meetings spread across hotel rooms in San Francisco where the industry’s annual gathering had taken place, not to say had been celebrated. Nobody knows if or when we will return to holding physical meetings. What the pandemic has shown us all is that a lot of time can be saved when interacting virtually: